Claritev Corporation
HealthcareNYSE:CTEV · New York Stock Exchange
-$1.14 today
Vol 0.12M · Avg 0.14M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $21.3M |
| Receivables | $140.9M |
| Other Current | $80.0M |
| Total Current Assets | $242.3M |
| PP&E (Net) | $357.1M |
| Goodwill | $2.4B |
| Intangible Assets | $1.8B |
| Other Non-current | $35.3M |
| Total Non-current Assets | $4.6B |
| Total Assets | $4.8B |
Analysis
Selected assets total $4.8B for Latest. The largest visible component is Goodwill at $2.4B, about 49.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.8M -0.2% | $16.8M -76.5% | $71.5M -78.6% | $334.0M +80.2% | $185.3M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $138.2M +23.8% | $111.6M +31.7% | $84.8M +7.4% | $78.9M -21.0% | $99.9M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $69.4M +250.0% | $19.8M +58.6% | $12.5M +22.6% | $10.2M +151.6% | $4.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $224.4M +27.8% | $175.5M -9.3% | $193.6M -56.7% | $446.7M +39.9% | $319.3M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $340.3M +10.2% | $308.7M +7.5% | $287.1M +11.7% | $257.1M +5.6% | $243.3M | $1.2B | $1.5B | $687.8M |
| Goodwill | $2.4B +0.1% | $2.4B -37.2% | $3.8B +3.3% | $3.7B -15.1% | $4.4B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $1.9B -15.3% | $2.2B -15.5% | $2.6B -10.4% | $2.9B -10.5% | $3.3B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 -100.0% | $15.0M | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $33.3M +50.8% | $22.1M +1.5% | $21.8M -0.5% | $21.9M +125.7% | $9.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $4.7B -6.3% | $5.0B -26.5% | $6.8B -2.2% | $6.9B -12.4% | $7.9B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $4.9B -5.1% | $5.2B -26.0% | $7.0B -5.5% | $7.4B -10.3% | $8.2B | $13.3B | $11.9B | $10.6B |
| Account Payables | $60.5M -30.0% | $86.3M +340.7% | $19.6M +47.3% | $13.3M +2.2% | $13.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $19.4M +46.4% | $13.3M +0.0% | $13.3M +0.0% | $13.3M +0.0% | $13.3M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $181.5M +438.7% | $33.7M -24.7% | $44.7M +29.4% | $34.6M +36.0% | $25.4M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $261.4M +22.2% | $213.8M +28.2% | $166.7M -5.2% | $175.8M +23.9% | $141.9M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $4.6B +1.9% | $4.5B -0.5% | $4.5B -4.4% | $4.7B -2.8% | $4.9B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $197.6M -39.4% | $325.8M -37.5% | $521.7M -18.4% | $639.5M -15.2% | $753.8M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$16.2M -551.1% | $3.6M -79.1% | $17.3M +598.8% | $2.5M -96.7% | $74.1M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $4.8B -1.2% | $4.9B -4.6% | $5.1B -5.8% | $5.4B -5.7% | $5.7B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $5.1B -0.2% | $5.1B -3.6% | $5.3B -5.8% | $5.6B -5.0% | $5.9B | $14.7B | $3.7B | $9.6B |
| Common Stock | $2.0K +0.0% | $2.0K +0.0% | $2.0K -97.0% | $67.0K +0.0% | $67.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$2.4B -13.3% | -$2.1B -329.6% | -$499.3M -43.6% | -$347.8M -254.5% | $225.1M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$4.2M +17.6% | -$5.1M +57.0% | -$11.8M | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $6.7M | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$167.2M -299.0% | $84.0M -95.1% | $1.7B -4.5% | $1.8B -23.6% | $2.3B | $9.1B | $7.7B | $3.3B |
| Total Debt | $4.6B +2.0% | $4.5B -0.6% | $4.6B -4.5% | $4.8B -2.9% | $4.9B | $724.2M | $410.6M | $399.4M |
| Net Debt | $4.6B +2.0% | $4.5B +0.6% | $4.5B +1.1% | $4.4B -6.2% | $4.7B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
AxoGen, Inc.
NASDAQ:AXGN
$2.29B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
InMode Ltd.
NASDAQ:INMD
$817.88M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Evolent Health, Inc.
NYSE:EVH
$539.91M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does CTEV have?
Claritev Corporation (CTEV) reported $16.81M in cash and equivalents in fiscal 2025.
How much debt does CTEV carry?
Claritev Corporation (CTEV) reported $4.63B of total debt, with net debt of $4.62B.
Explore More
Continue the stock analysis
Jump to another research area for this company.